Not available
Quote | Marinus Pharmaceuticals Inc. (NASDAQ:MRNS)
Last: | $1.205 |
---|---|
Change Percent: | 1.26% |
Open: | $1.2 |
Close: | $1.19 |
High: | $1.24 |
Low: | $1.19 |
Volume: | 208,857 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Marinus Pharmaceuticals Inc. (NASDAQ:MRNS)
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Marinus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Marinus stock or options between March 17, 2021 and May 7...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Marinus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Marinus stock or options between March 17, 2021 and May 7...
Message Board Posts | Marinus Pharmaceuticals Inc. (NASDAQ:MRNS)
Subject | By | Source | When |
---|---|---|---|
Did you add more here? This recovered | Cosa | investorshub | 04/19/2023 12:04:13 AM |
whytestocks: $MRNS News Article - Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for G | whytestocks | investorshangout | 03/22/2023 5:10:50 PM |
whytestocks: $MRNS News Article - Marinus Pharmaceuticals Appoints Christine Silverstein to its Boar | whytestocks | investorshangout | 01/30/2023 9:05:45 PM |
Thanks, I will look. | Cosa | investorshub | 01/23/2023 6:34:53 PM |
Ha, our time is coming for MRNS Cosa, | Ganz | investorshub | 01/20/2023 3:40:51 PM |
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law Firm PR Newswire LOS ANGELES , June 11, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing o...
NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons or entities who purchased or otherwise acquired Marinus P...